TABLE 6.

Histomorphometric evaluation of iliac bone biopsy specimens from animals receiving chronic low-dose PMPA treatment^a

Animal no.	Sexb	PMPA treatment	Bone structure measures							Bone formation dynamics							Osteoid and bone formation					Bone resorption
			BV/TV	BS/BV	Tb.Th	Tb.N	Tb.Sp	W.Th	It.Th	MS/BS	MAR	BFR/BS	BFR/BV	BFR/TV	Aj.AR	Ac.f	OS/BS	Ob.S/BS	O.Th	OV/BV	FP	ES/BS	Oc.S/BS	Rs.P + Rv.P
31007	M	−	45.61	15.86	126.09	3.62	150.34	19.08	87.93	45.47	1.33	220.33	349.49	159.41	1.74	11.55	34.75	5.50	8.77	4.75	10.98	8.33	3.68	2.63
31456	F	−	41.82	16.87	118.59	3.53	164.95	19.18	80.22	45.64	1.52	253.56	427.63	178.85	1.74	13.22	39.98	10.65	12.80	8.46	11.04	8.40	4.20	2.32
31121	M	+	28.52	21.52	92.93	3.07	232.92	19.38	54.18	42.05	1.14	174.99	376.59	107.40	1.60	9.03	29.99	13.20	8.43	5.45	12.12	14.83	10.00	6.00
31122	F	+	40.13	17.81	112.29	3.57	167.56	18.33	75.63	42.10	1.20	184.04	327.79	131.53	1.51	10.04	33.32	7.68	8.24	4.76	12.11	7.60	3.65	2.76

^aAnimals 31121 and 31122 were started on prolonged low-dose PMPA administration (10 mg/kg subcutaneously once daily) shortly after birth (Table 4). Animals 31007 and 31456 are age-matched control animals. Following calcein labeling, iliac bone biopsies were performed at approximately 3.5 years of age. Units and formulas are explained in Table 7.

^bM, male; F, female.